Brainstorm Cell Therapeutics removes Leerink Partners as ATM selling agent

BRAINSTORM CELL THERAPEUTICS INC.

Amendment No. 1 to Distribution Agreement dated April 2, 2024 removes Leerink Partners as agent.
Raymond James remains as the sole agent under the existing $100M ATM equity program.
Original Distribution Agreement was entered August 9, 2021; no change to offering size or terms.
Company's common stock trades on Nasdaq under ticker BCLI.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

BRAINSTORM CELL THERAPEUTICS INC. amended Distribution Agreement with Leerink Partners LLC (effective 2024-04-02).

Action: amendment
Agreement: atm program
Counterparty: Leerink Partners LLC
Effective: 2024-04-02

Exact text from the filing

On April 2, 2024, the Company entered into an amendment No. 1 to the Distribution Agreement (“Amendment No. 1”) pursuant to which Leerink Partners ceased to be an agent under the Distribution Agreement.

View on SEC.gov

380 material agreements filed in the last 30 days. Browse all material agreements →

BRAINSTORM CELL THERAPEUTICS INC. filing history →

Source: SEC EDGAR

accession 0001104659-24-042513

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.